Search the Newsreel

Central Garden & Pet (NASDAQ:CENT) Sets New 12-Month High on Strong Earnings

Natera (NASDAQ: NTRA) lifts 2026 outlook on $753M Q2 revenue

[10-Q] Concentra Group Holdings Parent, Inc. Quarterly Earnings Report

Concentra Group Holdings Parent Inc (CON) is scheduled to release its Q2

Central Puerto (CEPU) Projected to Post Earnings on Thursday

Sentral Reit Announces Interim Gross Income Distribution for Period from 1 January 2026 to 30 June 2026, Payable on September 18, 2026

Central Garden & Pet Co (CENT) (Q3 2026) Earnings Call Highlights: Organic Growth and ...

This article first appeared on GuruFocus. Net Sales: Declined 8% to $882 million, impacted by the exit of the Pet distribution business. Organic Net Sales: Rose 2% to $862 million, reflecting growth in both Garden and Pet segments. Non-GAAP Gross Profit: $318 million, down …

Will Algoma Central Corporation (ALC) Beat Estimates Again in Its Next Earnings Report?

Central Garden & Pet Company A (CENTA) shows split momentum before results

The consumer defensive stock has cooled in recent weekly returns, even as the longer lookback remains positive before earnings.

Natera executive (NASDAQ: NTRA) logs 3,410-share sale under Rule 10b5-1 plans

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ: NTRA), sold a total of 3,410 shares of common stock on August 3, 2026. These sales, conducted under Rule 10b5-1 plans, included shares sold to cover tax withholding obligations on RSU vesting and additional …

Natera (NTRA) co-founder sells 109 shares to cover RSU-related taxes

Jonathan Sheena, co-founder and director of Natera, Inc. (NTRA), sold 109 shares of common stock on August 3, 2026, at a price of $267.9893 per share. This sale was conducted to fulfill tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) …

Natera (NASDAQ: NTRA) CEO stock sales cover RSU taxes, 10b5-1 plan

Natera, Inc. CEO and President Steven Leonard Chapman sold a total of 3,076 shares of common stock on August 3, 2026. A portion of these sales, specifically 1,182 shares, was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units …

Natera (NTRA) CFO logs 795-share stock sales for taxes and Rule 10b5-1

Natera's Chief Financial Officer, Michael Burkes Brophy, reported two sales of common stock totaling 795 shares. These sales, executed on August 3 and August 4, 2026, were made to cover tax obligations related to RSU vesting and through a Rule 10b5-1 trading plan. After …

Earnings call transcript: Central Garden & Pet lifts Q3 2026 outlook

Key Points Interested in Central Garden & Pet Company? Here are five stocks we like better. Central Garden & Pet raised its fiscal 2026 adjusted EPS outlook to $2.85 or better from $2.70, despite reported third-quarter sales falling 8% to $882 million following its …

Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Entrada Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The brief report indicates the company's financial performance for the specified period. The full details are available through Refinitiv and other news sources on TradingView.

Central Bancompany, Inc. Posts Robust Earnings Momentum

Central Garden & Pet (NASDAQ:CENTA) Releases FY 2026 Earnings Guidance

Central Garden & Pet (NASDAQ:CENT) Updates FY 2026 Earnings Guidance

Central Garden & Pet (NASDAQ:CENTA) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

ADEN: Q2 2026 delivered higher sales, margin gains, and double-digit adjusted EPS growth amid soft markets

ADENTRA Delivers Margin Gains and EPS Growth in Soft Q2 Market

ADENTRA Reports Strong Q2 2026 Results

Entrada Therapeutics (NASDAQ: TRDA) details $82M H1 loss and $223M cash runway

Entrada Therapeutics reported a net loss of $42.8 million for Q2 2026 and $82.5 million for the first half of 2026, with collaboration revenue declining due to the completion of major research milestones. The company maintains a strong cash position of $223.0 million, expected …

Central Garden (CENT) Surpasses Q3 Earnings and Revenue Estimates

Central Garden (CENT) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $1.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Central Garden (CENTA) Tops Q3 Earnings and Revenue Estimates

Central Garden & Pet (NASDAQ:CENT) Exceeds Q2 CY2026 Expectations

Central Garden & Pet (NASDAQ:CENT) Exceeds Q2 CY2026 Expectations Pet company Central Garden & Pet (NASDAQ:CENT) reported Q2 CY2026 results exceeding the market's revenue expectations , but sales fell by 8.2% year on year to $882.4 million. Its non-GAAP profit of $1.54 per share …

Earnings Flash (CENT) Central Garden & Pet Company Reports Q3 Revenue $882.4M, vs. FactSet Est of $883.0M

Central Garden & Pet Company (CENT) reported its Q3 revenue at $882.4 million, slightly below FactSet's estimate of $883.0 million. This financial update follows another recent announcement where the company posted adjusted EPS of $1.54 per share, surpassing FactSet's estimate of $1.53. The company …

Concentra Group Holdings Parent, Inc. (NYSE: CON) director sells 130,000 shares

Concentra Group Holdings Parent, Inc. (NYSE: CON) director Robert A. Ortenzio sold 130,000 shares of common stock on August 3, 2026, at a weighted average price of $31.8412 per share. The sale, valued at $4.14 million, was executed indirectly through The Rocco A. Ortenzio …

Central Garden & Pet earnings on deck amid revenue headwinds

Central Garden & Pet is set to release its fiscal third-quarter earnings, with analysts expecting $1.51 EPS on $895.77 million in revenue. While profit is projected to increase sequentially, revenue is expected to decline year-over-year, prompting investors to focus on the company's ability to …

Central Asia Metals (LON:CAML) Given Buy Rating at Peel Hunt

Central Garden & Pet earnings on deck amid revenue headwinds By Investing.com

Central Garden & Pet is set to report its fiscal third-quarter earnings with analysts expecting an EPS of $1.51 on revenue of $895.77 million. Despite anticipated sequential EPS growth, revenue is forecast to decline, raising investor focus on the company's ability to maintain profitability …

Entrada Therapeutics publishes corporate presentation on genetic medicines pipeline for neuromuscular and inherited retinal diseases

Entrada Therapeutics announced upcoming clinical data catalysts for 2026 across Duchenne muscular dystrophy and myotonic dystrophy type 1. The company's ENTR-601-44 Phase 1/2 Cohort 1 showed significant improvement in Time to Rise and no serious adverse events. Future data releases include Cohort 1 open-label …

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) reported a narrower-than-expected Q2 loss of $1.01 per share, beating the Zacks Consensus Estimate of a $1.16 loss. The company also surpassed revenue estimates, posting $0.9 million for the quarter, although this was lower than the $1.95 million reported a …

Did Stronger Earnings, Dividend Hike and Buybacks Just Shift Central Pacific Financial's (CPF) Investment Narrative?

Central Pacific Financial Corp. (CPF) reported stronger second-quarter 2026 results, including higher net interest income and net income, along with a 3.4% increase in its quarterly dividend and significant share buybacks. These actions suggest a focus on capital return and may alter investor perception …

Entrada Therapeutics (Nasdaq: TRDA) reports Q2 2026 results and sets DMD, DM1 data timeline

Entrada Therapeutics (TRDA) reported a Q2 2026 net loss of $42.8 million and outlined upcoming clinical milestones for its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. The company held $223.0 million in cash, expected to fund operations into Q3 2027, …

Entrada Therapeutics reports Q2 2026 results: $223.0M cash; Q2 net loss $42.8M

Entrada Therapeutics reported its second-quarter 2026 financial results, showing a net loss of $42.8 million and cash, cash equivalents, and marketable securities totaling $223.0 million. The company expects its cash reserves to fund operations into Q3 2027. Entrada also provided updates on its clinical …

Entrada Therapeutics, Inc. 2026: Revenue $898K, EPS ($1.01) — 10-Q Summary

Entrada Therapeutics, Inc. reported its Q2 2026 results, showing collaboration revenue of $898K and a diluted loss per share of ($1.01). The company highlighted clinical advancements in its DMD programs, progress in its collaboration with Vertex, and an expected funding runway into Q3 2027 …